Krzysztof Jeziorski | Oncology | Best Researcher Award

Dr. Krzysztof Jeziorski | Oncology | Best Researcher Award 

Department of Gerontology and Public Health at National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

Dr. Krzysztof Grzegorz Jeziorski, MD, PhD, is a distinguished Polish oncologist with a career spanning over four decades in clinical and academic medicine. He has served as Associate Professor and Senior Assistant at the Maria Skłodowska-Curie National Research Cancer Institute in Warsaw since 1988 and continues to contribute as a Clinical Trials Consultant at the National Institute of Geriatrics, Rheumatology and Rehabilitation. Dr. Jeziorski’s professional path is marked by leadership in gastrointestinal cancer research, extensive clinical trial involvement, and international academic collaborations. A former Dean of the Faculty of Health Sciences and Social Sciences, he combines deep clinical expertise with academic excellence. He has participated in fellowships across Europe, including at the University of Oxford and the University of Padova. Renowned for his commitment to advancing cancer research, he continues to enhance his knowledge through postgraduate studies and remains actively engaged in both practice and education.

Professional Profile 

Scopus Profile
ORCID Profile 

Education

Dr. Jeziorski earned his medical degree from the Medical University of Warsaw, completing the I Medical Faculty. He later pursued advanced specialization, obtaining first and second-grade specialties in General Medicine and Chemotherapy of Cancer from the Medical Centre of Postgraduate Education. His passion for oncology led him to further achieve a specialty in Clinical Oncology and a Doctorate in Medical Sciences. In 2009, he was awarded the prestigious Habilitation degree from the Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology. Dr. Jeziorski has continually enriched his education through prestigious fellowships and academic programs, including at the Universities of Oxford, Padova, Brussels, and Cambridge. He completed several key international training programs in epidemiology and public health. Recently, he completed postgraduate studies in Clinical Trial Methodology and is currently pursuing an MBA in Clinical Research and Biomedical Innovation Management at the Medical University of Warsaw, demonstrating his continued commitment to academic and professional growth.

Experience

Dr. Jeziorski brings a wealth of experience from clinical, academic, and administrative roles. Since 1988, he has been a leading figure at the Maria Skłodowska-Curie National Research Cancer Institute in Warsaw, serving as Associate Professor and senior assistant in the Outpatient Department for GI Cancers. He has also been a Clinical Trials Consultant at the National Institute of Geriatrics, Rheumatology and Rehabilitation since 2015. Earlier in his career, he worked with institutions like the Polish Academy of Sciences and served as Dean at the State Higher School of Pope John Paul II in Biała Podlaska. His clinical foundation was established at the Central Hospital of the Medical Academy in Warsaw. Dr. Jeziorski has managed over 20 international clinical trials as a Principal Investigator, contributing significantly to cancer research. His experience integrates scientific leadership, teaching, and hands-on patient care, making him a well-rounded and respected professional in medical oncology and research.

Awards and Honors

While a detailed list of awards is not provided in the curriculum vitae, Dr. Jeziorski’s academic journey includes several significant milestones that reflect a career of distinction. He received his Second Grade Specialty in Chemotherapy of Cancer with distinction, signaling outstanding academic and clinical performance. His international fellowships at elite institutions such as the University of Oxford, University of Padova, and University of Cambridge were awarded on a competitive basis and recognize his academic merit and research potential. Additionally, his long-term appointments at top-tier research institutes and his role as a Dean suggest institutional recognition of his expertise and leadership. Acceptance into high-profile postgraduate and international research training programs—including the Erasmus Summer Program and WHO/IDF seminars—further highlight his professional standing. His ongoing pursuit of an MBA in Clinical Research reflects both personal ambition and recognition of his evolving role in biomedical innovation and management.

Research Focus on Oncology

Dr. Jeziorski’s primary research focus lies in the field of gastrointestinal oncology, where he has made sustained contributions through clinical trials and academic leadership. He has acted as Principal Investigator in over 20 international clinical trials and participated in numerous additional studies as a Sub-Investigator. His research emphasizes improving therapeutic strategies for gastrointestinal neoplasms, with a strong interest in translating scientific findings into clinical practice. Dr. Jeziorski combines rigorous methodological training with deep clinical insight, as demonstrated by his postgraduate studies in clinical trial methodology and his continued education in research management. His international fellowships enriched his approach to evidence-based medicine and interdisciplinary collaboration. Throughout his career, he has actively worked to integrate public health perspectives and epidemiology into oncology research. By maintaining roles in both clinical care and research, Dr. Jeziorski ensures his work remains patient-centered, innovative, and aligned with global advances in cancer treatment.

Publications Top Notes

  • Title: Artificial Intelligence in Oncology

    • Authors: Krzysztof Jeziorski, Robert Olszewski

    • Year: 2024

  • Title: Lost in Communication: Do Family Physicians Provide Patients with Information on Preventing Diet-Related Diseases?

    • Authors: Robert Olszewski, Justyna Obiała, Karolina Obiała, Jakub Owoc, Małgorzata Mańczak, Klaudia Ćwiklińska, Magdalena Jabłońska, Paweł Zegarow, Jolanta Grygielska, Marzena Jaciubek, et al.

    • Year: 2022

  • Title: Hyperthermia in Rheumatic Diseases. A Promising Approach?

    • Author: Krzysztof Jeziorski

    • Year: 2018

  • Title: HER2 Status in GI Adenocarcinoma (TRIO-013/LOGiC Trial)

    • Authors: Press M.F., Ellis C.E., Gagnon R.C., Jeziorski K., et al.

    • Year: 2017

  • Title: Preservation of Duodenal Passage and Quality of Life After Gastrectomy

    • Authors: Olesiński T., Szpakowski M., Saramak P., Rutkowski A., Jeziorski K.

    • Year: 2017

  • Title: Rheumatic and Oncological Diseases – Common Challenges

    • Author: Krzysztof Jeziorski

    • Year: 2017

  • Title: Lapatinib + Chemotherapy in HER2+ GI Cancers (LOGiC Trial)

    • Authors: Hecht J.R., Bang Y.-J., Qin S.K., Jeziorski K., et al.

    • Year: 2016

  • Title: Preoperative Chemoradiation vs Short-Course Therapy in Rectal Cancer

    • Authors: Bujko K., Wyrwicz L., Rutkowski A., Jeziorski K., et al.

    • Year: 2016

  • Title: Validation of QLQ-GINET21 for GI Neuroendocrine Tumors

    • Authors: Yadegarfar G., Friend L., Jeziorski K., et al.

    • Year: 2013

  • Title: Efficacy of Y-90 DOTATATE in GEP-NETs – Phase II Study

    • Authors: Cwikla J.B., Sankowski A., Jeziorski K.G., et al.

    • Year: 2009

  • Title: Radiological Efficacy of 90Y-DOTATATE in Midgut NETs

    • Authors: Cwikla J.B., Sankowski A., Jeziorski K.G., et al.

    • Year: 2009

  • Title: Abscesses After Splenectomy in Gastric/Cardia Cancer Surgery

    • Authors: Szpakowski M., Olesiński T., Jeziorski K., et al.

    • Year: 2007

  • Title: Chemotherapy for Hepatocellular and Biliary Duct Cancers

    • Author: Krzysztof Jeziorski

    • Year: 2007

  • Title: Imaging of Gastroenteropancreatic NETs – Polish Center Experience

    • Authors: Cwikla J.B., Nasierowska-Guttmejer A., Jeziorski K.G., et al.

    • Year: 2007

  • Title: Leptomeningeal Metastases of EGJ Adenocarcinoma – Case Report

    • Authors: Olesiński T., Jeziorski K., Szawłowski A.

    • Year: 2007

Conclusion

Dr. Krzysztof Jeziorski exemplifies a distinguished researcher and clinician whose contributions to gastrointestinal oncology span over four decades. His involvement in high-impact, multi-center clinical trials, coupled with authorship in internationally recognized journals such as Journal of Clinical Oncology, Annals of Oncology, and British Journal of Cancer, highlights both the breadth and relevance of his work. He has consistently collaborated with global experts and participated in pivotal studies that influence cancer treatment protocols. His recent engagement with artificial intelligence in oncology indicates a forward-thinking and adaptive research approach. Although citation metrics for many of his publications are not readily available, the scope, continuity, and quality of his work speak to his lasting impact on cancer research. Dr. Jeziorski’s blend of clinical excellence, academic leadership, and international collaboration positions him as a highly deserving candidate for the Best Researcher Award, with a legacy that bridges science, innovation, and patient-centered care.

Jed Jebali | Recherche | Best Researcher Award

Prof Dr. Jed Jebali | Recherche | Best Researcher Award

Doctor, institut pasteur de tunis, Tunisia

Dr. Jed Jebali is a seasoned researcher specializing in the study of snake venoms, particularly from the vipers, at the Institut Pasteur de Tunis. With a focus on the biochemical and pharmacological properties of venom components, Dr. Jebali has contributed significantly to the understanding of their anticancer and anti-inflammatory activities. She is currently a Maître de conférences at the Institut Pasteur de Tunis.

Profile

Scopus

Evaluation of Dr. Jebali Jed for the Best Researcher Award

Strengths for the Award

  1. Academic Background and Expertise: Dr. Jebali Jed has an extensive academic background in molecular biology, with a Doctorate and Habilitation universitaire à Diriger les Travaux de Recherche (HDR). This showcases a deep level of expertise and a strong foundation in the field.
  2. Research Focus and Impact: Dr. Jebali’s research primarily focuses on the biochemical and pharmacological properties of viper venoms, specifically their anti-cancer and anti-inflammatory activities. This research has significant implications for developing novel therapeutic agents.
  3. Publication Record: Dr. Jebali has published several research papers in reputable journals, including studies on the pharmacological effects of snake venom components and their potential therapeutic applications. The inclusion of recent publications in high-impact journals like “Current Neuropharmacology” and “International Journal of Molecular Sciences” underscores the relevance and quality of the research.
  4. Professional Experience: With over a decade of experience in teaching and research, Dr. Jebali has held positions from a contract teacher to a Biologist (Maître de conférences) at the Institut Pasteur de Tunis. This progression highlights a steady career growth and recognition within the scientific community.
  5. Collaborative Projects: The involvement in collaborative research projects, as evidenced by co-authored publications with multiple researchers, demonstrates the ability to work effectively in a team and contribute to multidisciplinary research efforts.

Areas for Improvement

  1. Broader Research Dissemination: While Dr. Jebali has a solid publication record, increasing participation in international conferences and presenting research findings to a broader audience could enhance visibility and impact.
  2. H-index Improvement: An H-index of 10 is commendable, but there is potential for growth. Engaging in high-impact research projects and targeting top-tier journals can help improve this metric, reflecting wider recognition and citation of the work.
  3. Grant Acquisition: Securing more research grants and funding can amplify the scope and scale of research projects, providing additional resources for innovative studies and collaborations.
  4. Mentorship and Leadership: Developing a stronger presence in mentorship roles and leading larger research teams or departments can further establish Dr. Jebali as a leading figure in the field, fostering the next generation of researchers.

🎓 Education

  • Nov 2020: Habilitation universitaire à Diriger les Travaux de Recherche (HDR), Institut Pasteur de Tunis. Thesis: “Les lectines de type C issues de venin de la vipère Macrovipera Lebetena: activités anti tumorales et anti-inflammatoire.”
  • Sep 2012: Ph.D. in Biology, Faculty of Sciences of Tunis (FST). Dissertation: “Les lectines de type C issues de la vipère Tunisienne Macrovipera lebetina: clonage, caractérisation génétique et expression dans les cellules embryonnaires du Rein Humain.”
  • Dec 2004: Master in Molecular and Cellular Biology. Dissertation: “Analyse moléculaire de la protéine LeIF des parasites du genre Leishmania: Modélisation Moléculaire comparée et Mutagenèse par délétion.”
  • Jun 2002: Bachelor’s in Life Sciences, Faculty of Sciences of Sfax (FSS).
  • Jun 1997: Baccalaureate in Experimental Sciences.

💼 Experience

  • 2010-2014: Contractual Lecturer at the Higher Institute of Biotechnology of Beja, University of Jendouba.
  • 2012-2014: Volunteer Postdoctoral Fellow at the Institut Pasteur de Tunis.
  • Oct 2014: Appointed as an Assistant Biologist at the Laboratory of Venoms and Therapeutic Biomolecules, Institut Pasteur de Tunis.
  • Oct 2016: Permanent position as Assistant Biologist at the Institut Pasteur de Tunis.
  • Sep 2022: Promoted to Biologist (Maître de conférences) at the Laboratory of Venom Biomolecules and Theranostic Applications, Institut Pasteur de Tunis.

🔬 Research Interests

Dr. Jebali’s research focuses on the biochemical and pharmacological analysis of viper venoms, specifically their interaction with integrins and their anticancer and anti-inflammatory properties. She has a strong background in molecular biology, contributing to the expression of various venom proteins and peptides.

📚 Publications Top Notes

  1. 2023: “Biphasic Hormetic-like Effect of Lebecetin, a C-type Lectin of Snake Venom, on Formalin-induced Inflammation in Mice” in Current Neuropharmacology. Read
  2. 2023: “CC5 and CC8, Two Disintegrin Isoforms from Cerastes cerastes Snake Venom Decreased Inflammation Response In Vitro and In Vivo” in International Journal of Molecular Sciences. Read
  3. 2022: “Investigation of the Renal Protective Effect of Combined Dietary Polyphenols in Streptozotocin-Induced Diabetic Aged Rats” in Nutrients. Read
  4. 2022: “Tunisian Native Mentha pulegium L. Extracts: Phytochemical Composition and Biological Activities” in Molecules. Read

📈 Cited by Articles

  • The publication on the hormetic-like effect of Lebecetin in Current Neuropharmacology has been cited by various research articles focusing on inflammation and neuropharmacology.
  • The study on disintegrin isoforms from Cerastes cerastes snake venom in International Journal of Molecular Sciences has attracted citations in the fields of molecular biology and inflammation research.
  • Research on renal protection by dietary polyphenols in Nutrients is frequently referenced in studies related to diabetes and renal health.
  • The work on Mentha pulegium L. extracts in Molecules is cited in research exploring phytochemistry and biological activities of plant extracts.

Conclusion

Dr. Jebali Jed is a strong candidate for the Best Researcher Award, with a robust academic background, impactful research focus, and a proven track record of publications and professional growth. The areas for improvement, such as increasing research dissemination, enhancing the H-index, securing more grants, and expanding mentorship roles, are achievable and would further solidify Dr. Jebali’s standing in the scientific community. Overall, Dr. Jebali’s contributions to the field of molecular biology and the study of viper venoms position them as a valuable and deserving contender for the award.